Aim To observe the beneficial effects of high dose atorvastatin sequential treatment on high sensitivity C-reactive protein (hs-CRP) and short-time major adverse cardiovascular events (MACE) in acute non-ST segment elevation myocardial infarction (NSTEMI) patients underwent elective percutaneous coronary intervention (PCI). Methods One hundred patients with NSTEMI from September 2009 to April 2012 underwent elective PCI were randomly divided into two groups:high dose atorvastatin sequential treatment group (group A) and positive control group (group B).All patients were given 80 mg atorvastatin instantly and then 40 mg once a day. One the basis of hydration therapy, group A received additional 40 mg atorvastatin at 6 hours before PCI. Lipid levels and hs-CRP were measured and compared 24 hours and 48 hours post-PCI. 12-week incidence of MACE was done in a follow-up. Results Lipid levels had no significant change after PCI (P＞0.05). In comparison with the levels before PCI, hs-CRP increased significantly in the two groups (P＜0.05), and group A was significantly lower than group B (P＜0.05). The incidence of MACE was similar in the two groups (4% vs. 6%, P＞0.05). The two groups showed no clinically significant liver enzymes and elevated muscle enzymes, and there were not adverse reactions in both groups. Conclusion High dose atorvastatin sequential therapy can be a certain degree of inhibition of endothelial inflammatory response in NSTEMI patients after PCI, and the security is good, but can’t decrease the short-time MACE.